FeesSafety
Pluang+

Top 10 high-growth dividend stocks selected for strong returns and sustainability over 3+ years

Analyst Insights
24 Oct 2026
Seeking Alpha
View Source
Neutral
Top 10 high-growth dividend stocks selected for strong returns and sustainability over 3+ years

The article outlines a method for choosing high-growth dividend stocks based on dividend growth and sustainability rather than just high yields. Using proprietary quantitative and qualitative models, the author narrowed down nearly 500 dividend stocks to a top 10 list that balances sector diversity and positive momentum. This portfolio has outperformed the S&P 500 with a 27% annualized return over more than three years, compared to 18% for the index. The list is intended for investors focused on long-term accumulation and income growth, with a caution to conduct personal due diligence before investing.

Our Top 10 High Growth Dividend Stocks are highlighted here with Pluang's market data for context. For readers following US stocks, here is Pluang's market snapshot as of Oct 24, 2026 19:01 WIB: Out of 150 priced US stocks tradable on Pluang, 46 rose and 102 fell today. Notable movers include FCEL at USD 11.11 with a 1-day change of -4.06% and Pluang order activity of 43% Sell / 57% Buy, UAL at USD 97.93 with a 1-day change of -3.99% and 0% Sell / 100% Buy order activity, and AAL at USD 12.11 with a 1-day change of -3.89% and 48% Sell / 52% Buy order activity. Typical hold times on Pluang range from 46 to 59 days among these stocks.

More News

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
Arthur Hayes warns HYPE token may underperform ETH and ZEC despite proven demand for on-chain perpetual futures.

Arthur Hayes warns HYPE token may underperform ETH and ZEC despite proven demand for on-chain perpetual futures.

Arthur Hayes, BitMEX founder, acknowledged that Hyperliquid has successfully proven demand for on-chain perpetual futures markets with a working product and active trading volume. However, he warned that HYPE has become a crowded consensus trade, red...

Market News
Neutral
4 hours ago
Canton Network approves token burn to replace license fees starting Q1 2027, impacting token economics.

Canton Network approves token burn to replace license fees starting Q1 2027, impacting token economics.

The Canton Network's Super Validators approved proposal CIP-0129 on October 21, 2026, to implement a universal burn mechanism where dedicated synchronizers will burn Canton Coin to pay for network traffic instead of paying software license fees to Di...

Protocol Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App